Akeso Reports 7‑month Median PFS for Cadonilimab Combo in PD-(L)1‑resistant NSCLC

Why It Matters

The updated Phase Ib/II data address a critical gap in lung‑cancer treatment: effective therapies after PD-(L)1 inhibitor resistance. By delivering a median PFS of 7 months and a high disease‑control rate, the cadonilimab‑based regimen could become a new standard for second‑line care, potentially improving survival and quality of life for thousands of patients worldwide. Moreover, the molecular evidence of ctDNA clearance suggests that the combination may achieve deep, durable responses, a finding that could influence biomarker‑driven trial designs across oncology. From a commercial perspective, success in a Phase III trial would add a high‑value asset to Akeso’s pipeline, strengthening its position among biopharma firms focused on bispecific antibodies. The data also signal to investors that Akeso’s Tetrabody platform can generate differentiated immuno‑oncology products capable of overcoming resistance mechanisms that have limited other agents.

Key Takeaways

• Median progression‑free survival of 7.0 months in PD-(L)1‑resistant advanced NSCLC
• 6‑month PFS rate of 55.7% and disease‑control rate of 95.2%
• Objective response rate of 26.2% with median duration of response of 6.0 months
• Grade ≥ 3 treatment‑related adverse events observed in 14.0% of patients, no treatment‑related deaths
• ctDNA clearance after one cycle linked to median PFS of 9.1 months

Pulse Analysis

Akeso’s latest readout arrives at a moment when the oncology market is grappling with the limits of checkpoint inhibition. While PD-(L)1 antibodies have become first‑line staples, resistance emerges in a sizable fraction of patients, prompting a scramble for next‑generation strategies. Cadonilimab’s bispecific design—simultaneously engaging two distinct tumor antigens—offers a mechanistic advantage that may explain the observed durability and high disease‑control rates. The addition of anlotinib, a multi‑targeted tyrosine‑kinase inhibitor, and docetaxel, a cytotoxic backbone, creates a triple‑hit approach that attacks tumor growth on several fronts.

Historically, second‑line options after checkpoint failure have been limited to chemotherapy or modestly effective targeted agents, often with considerable toxicity. Akeso’s safety data, showing a 14% rate of grade ≥ 3 events and no deaths, suggest a tolerable risk profile that could make the regimen attractive to clinicians wary of overtreatment. If the forthcoming Phase III trial confirms these signals, the combination could capture a sizable share of the $5‑billion global market for post‑PD-(L)1 NSCLC therapies.

Looking ahead, the ctDNA findings may catalyze a shift toward molecular monitoring as a decision‑making tool in immuno‑oncology. Demonstrating that early ctDNA clearance correlates with longer PFS could encourage sponsors to embed liquid‑biopsy endpoints in future trials, potentially accelerating drug development cycles. Akeso’s ability to leverage its AI‑driven R&D platform to identify synergistic partners may also set a precedent for rapid, data‑backed combination design, positioning the company as a nimble challenger in a space dominated by larger incumbents.